ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,277.51
0.80%
US Tech 100
18,064.80
0.02%
Dow Jones
38,686.32
1.51%
Brent Oil
81.295
0.00%
Bitcoin
67,657.61
0.26%
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Cryptocurrencies
  4. BFNX
  5. (Bitfinex:REPBTC)

  6. (Bitfinex:REPBTC) News

REPBTC

(REPBTC)

Unknown symbol
Date:
Sort by:
DateTimeSourceHeadlineSymbolCompany
06/01/20248:05AMGlobeNewswire Inc.Y-mAbs Announces New Interim Analysis of Phase 2 Data for Naxitamab at 2024 ASCO Annual MeetingNASDAQ:YMABY mAbs Therapeutics Inc
06/01/20248:05AMPR Newswire (US)Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024NASDAQ:JAZZJazz Pharmaceuticals PLC
06/01/20248:01AMAlliance NewsAlliance NewsEXECUTIVE CHANGES: Pendragon chair to remain chair of Pinewood TechLSE:TGRTirupati Graphite Plc
06/01/20248:01AMAlliance NewsAlliance NewsEXECUTIVE CHANGES: Pendragon chair to remain chair of Pinewood TechLSE:TPXTpximpact Holdings Plc
06/01/20248:01AMAlliance NewsAlliance NewsEXECUTIVE CHANGES: Pendragon chair to remain chair of Pinewood TechLSE:PIERBrighton Pier Group Plc (the)
06/01/20248:01AMAlliance NewsAlliance NewsEXECUTIVE CHANGES: Pendragon chair to remain chair of Pinewood TechLSE:LPALpa Group Plc
06/01/20248:01AMAlliance NewsAlliance NewsEXECUTIVE CHANGES: Pendragon chair to remain chair of Pinewood TechLSE:PINEPinewood Technologies Group Plc
06/01/20248:01AMAlliance NewsAlliance NewsEXECUTIVE CHANGES: Pendragon chair to remain chair of Pinewood TechLSE:PYCPhysiomics Plc
06/01/20248:01AMAlliance NewsAlliance NewsEXECUTIVE CHANGES: Pendragon chair to remain chair of Pinewood TechLSE:TAVITavistock Investments Plc
06/01/20248:01AMAlliance NewsAlliance NewsEXECUTIVE CHANGES: Pendragon chair to remain chair of Pinewood TechLSE:RTOPRegtech Open Project Plc
06/01/20248:01AMAlliance NewsAlliance NewsEXECUTIVE CHANGES: Pendragon chair to remain chair of Pinewood TechLSE:RTOPRegtech Open Project Plc
06/01/20248:00AMBusiness WireMassive Bio to Unveil Drug Utilization Optimizer (DUO) at ASCO Annual Meeting 2024
06/01/20248:00AMGlobeNewswire Inc.Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024NASDAQ:MOLNMolecular Partners AG
06/01/20248:00AMGlobeNewswire Inc.CryptoHeap Targets Top Position in Crypto Staking Industry Before Bull Run Concludes
06/01/20248:00AMBusiness WirePfizer’s ADCETRIS® Regimen Produces Clinically Meaningful Improvement in Overall Survival in Patients with Relapsed/​Refractory Diffuse Large B-cell Lymphoma (DLBCL)NYSE:PFEPfizer Inc
06/01/20248:00AMBusiness WireKRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung CancerNYSE:BMYBristol Myers Squibb Co
06/01/20248:00AMBusiness WireGilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI CancersNYSE:RCUSArcus Biosciences Inc
06/01/20248:00AMGlobeNewswire Inc.Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual MeetingNASDAQ:KYMRKymera Therapeutics Inc
06/01/20248:00AMBusiness WireTakeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin LymphomaNYSE:PFEPfizer Inc
06/01/20248:00AMBusiness WireIvonescimab Manuscript for HARMONi-A Clinical Trial Results Published in JAMANASDAQ:SMMTSummit Therapeutics Inc
06/01/20248:00AMBusiness WireGilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI CancersNYSE:RCUSArcus Biosciences Inc
06/01/20248:00AMBusiness WireAccutar Biotechnology Presents Phase 1 Data of AC699 Monotherapy in Patients with ER+ / HER2- Breast Cancer at ASCO 2024
06/01/20248:00AMGlobeNewswire Inc.OkayCoin CEO Releases Key Strategies to Maximize Investor Returns on Staking Platform
06/01/20248:00AMBusiness WireGilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI CancersNASDAQ:GILDGilead Sciences Inc
06/01/20248:00AMGlobeNewswire Inc.Purple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic CancerNASDAQ:PPBTPurple Biotech Ltd
06/01/20248:00AMBusiness WireGilead and Arcus Announce Anti-TIGIT Domvanalimab Plus Zimberelimab and Chemotherapy Exceeded One Year of Median Progression-Free Survival as a First-Line Treatment for Upper GI CancersNASDAQ:GILDGilead Sciences Inc
06/01/20248:00AMBusiness WireTakeda and Pfizer Announce Four-Year Results from Positive Phase 3 HD21 Trial of Additional ADCETRIS® (brentuximab vedotin) Combination in Frontline Hodgkin LymphomaNYSE:TAKTakeda Pharmaceutical Company Ltd
06/01/20248:00AMGlobeNewswire Inc.Immunocore presents KIMMTRAK clinical data demonstrating that patients with stable disease and confirmed tumor reduction have similar clinical outcomes to patients with partial responseNASDAQ:IMCRImmunocore Holdings PLC
06/01/20248:00AMPR Newswire (US)Updated Data from the Phase 1/2 Study of Olomorasib in KRAS G12C-Mutant Advanced Solid Tumors Presented at the 2024 ASCO® Annual MeetingNYSE:LLYEli Lilly and Co
06/01/20248:00AMPR Newswire (US)BALEAF & SOJOS to host "Summer it up" summer fashion extravaganza!

Your Recent History

USOTC
HMBL
HUMBL (PK)
AMEX
FOXO
FOXO Technologies
USOTC
DRNK
NoHo (PK)
USOTC
RSPI
RespireRx Pharmaceuticals (PK)
USOTC
CATV
4Cable TV (PK)
USOTC
TPTW
TPT Global Tech (PK)
USOTC
CYDY
CytoDyn (QB)
USOTC
GNCP
GNCC Capital (CE)
USOTC
IFUS
Impact Fusion (PK)
NASDAQ
COOP
Mr Cooper
NASDAQ
DJT
Trump Media and Technology
USOTC
KEGS
1812 Brewing (PK)
USOTC
CEOS
CeCors (PK)
USOTC
FSRN
Fisker (PK)
USOTC
CGAC
Code Green Apparel (PK)
NASDAQ
AMRN
Amarin
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved